AstraZeneca is to sell European rights to its cholesterol drug Crestor (rosuvastatin) to Germany’s Grunenthal. Crestor is a statin and at its peak generated annual revenues of more than $7 ...

For almost 60 years, measuring cholesterol levels in the blood has been the best way to identify individuals at high risk of ...

AstraZeneca Plc’s Chief Executive Officer Pascal Soriot warned that trade tariffs are not the best way to manage pharmaceuticals and that drugmakers are calling for no additional US levies on ...

(NewsNation) — AstraZeneca’s experimental pill has shown promise in reducing “bad” cholesterol, raising expectations for more convenient alternatives in treatment options. AstraZenca is ...

Inflammation is likely a key player in atherosclerosis and related cardiovascular events, but questions remain about its role ...

Australian study finds no adverse impact of repeated Covid vaccinations on metabolism, inflammation, or cardiovascular ...

The researchers also reported improvements in total cholesterol, non-HDL cholesterol ... than 50% LDL cholesterol reduction,” Koren said. AstraZeneca is investigating the potential of AZD0780 ...

Q1 2025 Earnings Conference Call April 29, 2025 6:45 AM ETCompany ParticipantsAndy Barnett - Head of IRPascal Soriot ...

An investigational PCSK9 inhibitor with a different mechanism from existing drugs in this class has been shown to safely and ...